Associated Disease Details
| Disease ID: | I06 |
| DO ID: | 811 |
| Disease Name: | Lipodystrophy |
| Definition: | A connective tissue disease that is characterized by marked reduction, absence, and/or the redistribution of adipose tissue. https://www.ncbi.nlm.nih.gov/pubmed/25690482, https://www.ncbi.nlm.nih.gov/pubmed/25833179 |
| Synonyms: | Acquired generalized lipodystrophy; Acquired partial lipodystrophy; Familial generalized lipodystrophy; Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy |
| Class: | disease of anatomical entity/ musculoskeletal system disease/ connective tissue disease |
| Related Drugs: | Metreleptin; Tesamorelin |
| Mechanism: | Severe fatty liver disease develops early in lipodystrophic mice and progresses to advanced nonalcoholic steatohepatitis with highly dysplastic liver nodules. The liver injury is propagated by lipotoxicity and is associated with improved blood glucose levels. |
| Reference (PMIDs): | 27207510 |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00029 | 35250856 | Front Endocrinol (Lausanne) | Not Enough Fat: Mouse Models of Inherited Lipodystrophy. | Details |
| A00656 | 35013417 | Sci Rep | Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver. | Details |
| A01485 | 34728268 | Presse Med | Complications of lipodystrophy syndromes. | Details |
| A01881 | 34574647 | Int J Environ Res Public Health | Bone Mineral Density in Congenital Generalized Lipodystrophy: The Role of Bone Marrow Tissue, Adipokines, and Insulin Resistance. | Details |
| A01986 | 34540943 | Visc Med | Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). | Details |
| A02667 | 34292171 | Eur J Endocrinol | A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies. | Details |
| A03782 | 33865898 | Metabolism | Collagen β(1-O) galactosyltransferase 2 deficiency contributes to lipodystrophy and aggravates NAFLD related to HMW adiponectin in mice. | Details |
| A03794 | 33862045 | Metabolism | Determinants of hepatic insulin clearance - Results from a Mendelian Randomization study. | Details |
| A04067 | 33771728 | Mol Metab | Ube2i deletion in adipocytes causes lipoatrophy in mice. | Details |
| A06058 | 33025629 | NMR Biomed | In vivo absolute quantification of hepatic γ-ATP concentration in mice using 31 P MRS at 11.7 T. | Details |
| A07231 | 32573497 | JCI Insight | Leptin decreases de novo lipogenesis in patients with lipodystrophy. | Details |
| A07236 | 32572196 | Nat Biomed Eng | Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin. | Details |
| A07302 | 32548202 | ACG Case Rep J | Hepatic Steatosis Resulting From LMNA-Associated Familial Lipodystrophy. | Details |
| A08822 | 31978277 | Mol Nutr Food Res | Lipoatrophy-Associated Insulin Resistance and Hepatic Steatosis are Attenuated by Intake of Diet Rich in Omega 3 Fatty Acids. | Details |
| A10298 | 31393852 | JCI Insight | Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma. | Details |
| A10317 | 31388628 | Hepatol Commun | Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis. | Details |
| A10722 | 31222048 | Nat Commun | Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis. | Details |
| A10893 | 31136997 | Top Antivir Med | Fatty liver disease in persons with HIV infection. | Details |
| A10905 | 31131845 | Clin Infect Dis | Natural Course of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Patients With Human Immunodeficiency Virus With and Without Combination Antiretroviral Therapy-associated Lipodystrophy: A 16-Year Follow-up Study. | Details |
| A11043 | 31071311 | Metabolism | Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. | Details |